Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Chemodenervating pharmaceutical as anti-inflammatory agent

a technology of chemodenervating pharmaceutical and denervating tissue, which is applied in the field of chemodenervating pharmaceutical as anti-inflammatory agent, can solve the problems of pain or subjective adverse sensory experience, inability to explain certain medical observations regarding the use of chemodenervating agents, and inability to achieve long-lasting action, reduce inflammation, and reduce inflammation

Inactive Publication Date: 2009-06-11
REVANCE THERAPEUTICS INC
View PDF21 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes the use of low dosages of the chemical substance botulinum toxin to reduce inflammation and treat various diseases associated with inflammation. The use of low dosages of this substance has been found to block the release of histamine and other preformed mediators associated with inflammation. The patent also explains how this substance works by inhibiting the inflammatory response, reducing the formation of edema, erythema, and other symptoms associated with inflammation. The use of low dosages of botulinum toxin has been found to be effective in treating conditions such as allergic blepharospasm, uveitis, and inflammatory bowel disease. The patent also mentions the role of mast cells in inflammation and the importance of tumor necrosis factor alpha in modulating mast cell activity. Overall, the patent describes a new use of a known substance to treat inflammation and the development of a new method to reduce inflammation in the body.

Problems solved by technology

Unfortunately, inflammatory reactions intrinsically may have destructive effects on tissue and organ structure and function, and may lead to painful or subjectively adverse sensory experiences.
Despite the known tissue effects from regional injections of botulinum toxin, certain medical observations regarding the use of chemodenervating agents can not be easily explained by such denervating tissue effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chemodenervating pharmaceutical as anti-inflammatory agent
  • Chemodenervating pharmaceutical as anti-inflammatory agent
  • Chemodenervating pharmaceutical as anti-inflammatory agent

Examples

Experimental program
Comparison scheme
Effect test

case i

[0036]A 53-year-old woman had a history of Bell's Palsy five years prior to being evaluated for asymmetric facial movements from synkinesis. The facial movements were causing involuntary eyelid closure. Additionally, she noted abnormality in forehead creases and desired achieving facial forehead crease wrinkle symmetry by injection of botulinum into the frontalis muscle. After exercising, she noted that she would traditionally break out in hives, eg. urticaria, throughout her body, with the facial region being most severely involved. This urticarial reaction was closely associated with itching.

[0037]Two weeks after botulinum toxin injection at a dose of 2.5 units per injection site, an unusual phenomenon was noted on her forehead after exercising. An area measuring three to four centimeters around each injection area was protected from hive, itching or erythema. Other areas of the face were involved in the usual hive, erythema and flushing reaction experienced with exercising. The p...

case ii

[0040]A 44-year old woman with interest in having glabellar lines reduced with botulinum toxin experienced generally facial flushing and swelling sometimes associated with headache following extreme exertion. After regional botulinum toxin was administered at a dose of 5 units, an area with diameter measuring 25 mm around the injection sites was protected from the flushing and abnormal sensory effect associated with such exertion. She noted this protective effect lasted 10-14 weeks.

[0041]FIG. 2 is a photograph of this woman within three days after injection, showing the blocking effect on heat release, vasodilation, erythema and edema, which effect expands to its maximum in 12 days, and persists for at least four months.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
heataaaaaaaaaa
permeabilityaaaaaaaaaa
Login to View More

Abstract

Pharmaceutical application of a chemodenervating agent, particularly botulinum toxin, reduces inflammatory response and serves as an anti-inflammatory agent without systemic side effects and with long duration action, on the order of 12-24 weeks. In one embodiment, the effective dosage for allergy provoked inflammation reduction is an order of magnitude less than dosages associated with treatment of regional movement diseases, since the agent works to reduce inflammation by reducing histamine and other preformed mediator releases associated with mast cell degranulation.

Description

FIELD OF INVENTION[0001]This invention relates to the use of chemodenervating agents in the treatment of disease, and more particularly to its use as an anti-inflammatory agent.BACKGROUND OF THE INVENTION[0002]Immunity and inflammation are forms of physiologic processes defined as the body's response against foreign substances such as antigens or, in some cases, itself, autoantigens, or some form of damaging biologic or mechanical insult. The process often involves the production of antibodies by type B lymphocytes which interact with foreign substances and subsequently destroy or inactivate the antigen using a number of cellular and chemical amplification systems and regulation systems such as complement, arachidonic acid metabolites such as prostaglandin and leukotrienes, cytokines, preformed mediators such as serotonin and histamine, and enzymes. Inflammatory responses occur in conjunction and as a result of the immune recognition process and functions to provide the basic tissue...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/08A61P29/00
CPCA61K38/4893A61K45/06A61K2300/00A61P29/00
Inventor BORODIC, GARY E.
Owner REVANCE THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com